<!DOCTYPE html>
<html>
	<head>
		<meta charset="utf-8">
		<title></title>
		<script src="http://code.jquery.com/jquery-2.1.1.min.js"></script>
		<link href="https://cdn.jsdelivr.net/npm/bootstrap@5.1.3/dist/css/bootstrap.min.css" rel="stylesheet">
		<script src="https://cdn.jsdelivr.net/npm/bootstrap@5.1.3/dist/js/bootstrap.bundle.min.js"></script>
		<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap-icons@1.7.2/font/bootstrap-icons.css">
		<link rel="stylesheet" href="https://unpkg.com/bootstrap-table@1.19.1/dist/bootstrap-table.min.css">
		<script src="https://unpkg.com/bootstrap-table@1.19.1/dist/bootstrap-table.min.js"></script>
		<script type="text/javascript" src="js/echarts.js"></script>
		<script type="text/javascript" src="js/biore.js"></script>
		<style type="text/css">
		.justify-content-center{
			margin: 0px 100px;
		}
		.card{
			margin: 10px 0px;
		}
		</style>
	</head>
	<body>
		<div class="shadow p-3 mb-5 bg-body rounded">
		    <header class="d-flex flex-wrap justify-content-center py-3">
		      <a href="/" class="d-flex align-items-center mb-3 mb-md-0 me-md-auto text-dark text-decoration-none">
		        <svg class="bi me-2" width="40" height="32"><use xlink:href="#bootstrap"></use></svg>
		        <span class="fs-4">BIORE</span>
		      </a>
		
		      <ul class="nav nav-pills">
		        <li class="nav-item"><a href="#" class="nav-link active" aria-current="page">Home</a></li>
		        <li class="nav-item"><a href="#" class="nav-link">Features</a></li>
		        <li class="nav-item"><a href="#" class="nav-link">Pricing</a></li>
		        <li class="nav-item"><a href="#" class="nav-link">FAQs</a></li>
		        <li class="nav-item"><a href="#" class="nav-link">About</a></li>
		      </ul>
		    </header>
		</div>
		
		<div class="container">
			<div class="row">
				
			  <div class="col-2">
			    <input type="text" id="t1" class="form-control" placeholder="BRCA1" aria-label="First name">
			  </div>
			  <div class="col-2">
			    <input type="text" class="form-control" placeholder="BRCA2" aria-label="Last name">
			  </div>
			  <div class="col-1">
			    <button type="submit" class="btn btn-primary">serch</button>
			  </div>
			</div>
			
			
		</div>
		
		<div class="container">
			<div class="row">
				
			
			<div class="col-3">
				<div class="list-group" style="margin: 10px 0px;">
					<label class="list-group-item d-flex gap-2">
						<input class="form-check-input flex-shrink-0" type="radio" name="listGroupRadios" id="listGroupRadios1" value="" checked="">
						<span>single<small class="d-block text-muted">With support text underneath to add more detail</small></span>
					</label>
					<label class="list-group-item d-flex gap-2">
						<input class="form-check-input flex-shrink-0" type="radio" name="listGroupRadios" id="listGroupRadios2" value="" checked="">
						<span>pair<small class="d-block text-muted">With support text underneath to add more detail</small></span>
					</label>
					
				</div>
				
			</div>
			<div class="col-9">
			
			<div class="card">
			<div class="card-body">
				<h5 class="card-title"><a href="localhost:9900/data" style='color:black;text-decoration: none;'> Lung Cancer Group (SLCG) phase II trial, the combination of BRCA1 and receptor-associated protein<i class='bi bi-link-45deg'></i></a></h5>
			Despite dramatic advances in cancer research setting, breast cancer remains a major health problem and represents currently a top biomedical research priority. Worldwide, breast cancer is the most common cancer affecting women, and its incidence and mortality rates are expected to increase significantly the next years.
			</div>
			</div>
			
			<div class="card">
			<div class="card-body">
			<h5 class="card-title">Spanish Lung Cancer Group (SLCG) phase II trial, the combination of BRCA1 and receptor-associated protein<i class='bi bi-link-45deg'></i></h5>
			Despite dramatic advances in cancer research setting, breast cancer remains a major health problem and represents currently a top biomedical research priority. Worldwide, breast cancer is the most common cancer affecting women, and its incidence and mortality rates are expected to increase significantly the next years.
			</div>
			</div>
			
			<div class="card">
			<div class="card-body">
				<h5 class="card-title">Spanish Lung Cancer Group (SLCG) phase II trial, the combination of BRCA1 and receptor-associated protein<i class='bi bi-link-45deg'></i></h5>
			Despite dramatic advances in cancer research setting, breast cancer remains a major health problem and represents currently a top biomedical research priority. Worldwide, breast cancer is the most common cancer affecting women, and its incidence and mortality rates are expected to increase significantly the next years.
			</div>
			</div>
			
			<div class="card">
			<div class="card-body">
				<h5 class="card-title">Spanish Lung Cancer Group (SLCG) phase II trial, the combination of BRCA1 and receptor-associated protein<i class='bi bi-link-45deg'></i></h5>
			Despite dramatic advances in cancer research setting, breast cancer remains a major health problem and represents currently a top biomedical research priority. Worldwide, <span class="bg-success text-white">breast cancer</span> is the most common cancer affecting women, and its incidence and mortality rates are expected to increase significantly the next years.
			</div>
			</div>
			
			<div class="card">
			<div class="card-body">
				<h5 class="card-title">Spanish Lung Cancer Group (SLCG) phase II trial, the combination of BRCA1 and receptor-associated protein<i class='bi bi-link-45deg'></i></h5>
			Despite dramatic advances in <span class="bg-warning text-dark">cancer</span> research setting, breast cancer remains a major health problem and represents currently a top biomedical research priority. Worldwide, breast cancer is the most common cancer affecting women, and its incidence and mortality rates are expected to increase significantly the next years.
			</div>
			</div>
			
			<div class="card">
			<div class="card-body">
				<h5 class="card-title">Spanish Lung Cancer Group (SLCG) phase II trial, the combination of BRCA1 and receptor-associated protein<i class='bi bi-link-45deg'></i></h5>
			Despite dramatic advances in cancer research setting, breast cancer remains a major health problem and represents currently a top biomedical research priority. Worldwide, breast cancer is the most common cancer affecting women, and its incidence and mortality rates are expected to increase significantly the next years.
			</div>
			</div>
			
			<div class="card">
			<div class="card-body">
				<h5 class="card-title">Spanish Lung Cancer Group (SLCG) phase II trial, the combination of BRCA1 and receptor-associated protein<i class='bi bi-link-45deg'></i></h5>
			Despite dramatic advances in cancer research setting, breast cancer remains a major health problem and represents currently a top biomedical research priority. Worldwide, breast cancer is the most common cancer affecting women, and its incidence and mortality rates are expected to increase significantly the next years.
			</div>
			</div>
			
			</div>
			</div>
			
		</div>
	</body>
</html>
